A Dose-Finding Study Of Nanoparticle Albumin-Bound Paclitaxel Plus Cisplatin In Patients With Metastatic Nasophyngeal Carcinomas.

6049 Background: Nanoparticle albumin-bound paclitaxel (Abraxane, ABX), is a novel formulation of paclitaxel that has proved superior efficacy compared with conventional paclitaxel in the treatment of several metastatic cancers. We undertook this trial to determine the optimal dose and to preliminarily aseess efficacy of ABX plus cisplatin (DDP) in nasopharyngeal carcinoma (NPC). Methods: This was an open-label, nonrandomized study. Patients with metastatic NPC who were previously untreated or failed the standard treatment (radiochemotherapy or first-line chemotherapy) were enrolled sequentially into three cohorts (23 patients/cohort, N=69) to receive DDP 75 mg/m2 q3w plus ABX 260mg/m2 q3w (cohort 1), or 140mg/m2 d1, 8 q3w (cohort 2) or weekly ABX 100mg/m2(cohort 3), respectively. Recruitment of any cohort would be deceased if more than one third of patients experienced dose-limiting toxicities (DLTs). Results: All clinical features were balanced among cohorts, including sex, age, histology, proportion of...